Aster Capital Management DIFC Ltd Buys New Stake in Cencora, Inc. $COR

Aster Capital Management DIFC Ltd bought a new stake in Cencora, Inc. (NYSE:COR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,721 shares of the company’s stock, valued at approximately $1,257,000. Cencora comprises approximately 0.6% of Aster Capital Management DIFC Ltd’s holdings, making the stock its 28th biggest holding.

Several other large investors have also recently bought and sold shares of COR. Norges Bank purchased a new position in shares of Cencora during the fourth quarter worth about $822,506,000. Marshall Wace LLP grew its holdings in shares of Cencora by 518.9% during the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Cencora by 528.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after purchasing an additional 1,241,186 shares during the last quarter. Viking Global Investors LP grew its holdings in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Cencora by 4.1% during the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after purchasing an additional 916,506 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $281.58 on Tuesday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a market capitalization of $54.78 billion, a price-to-earnings ratio of 21.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The firm has a 50-day simple moving average of $288.36 and a 200-day simple moving average of $326.67. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same quarter last year, the company posted $4.42 EPS. Cencora’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Cencora announced that its Board of Directors has approved a share buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on COR shares. Citigroup dropped their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Wells Fargo & Company dropped their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Finally, Robert W. Baird dropped their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.